• / Free eNewsletters & Magazine
  • / My Account
Home>FDA approves Bristol-Myers Squibb's Opdivo to treat lung cancer

FDA approves Bristol-Myers Squibb's Opdivo to treat lung cancer

3party Content

Wed, 4 Mar 2015

The U.S. Food and Drug Administration said Wednesday it has approved Bristol-Myers Squibb Co.'s (BMY) Opdivo as a treatment for lung cancer, the leading cause of cancer death in the country. Opdivo has already been approved for patients with unresectable (cannot be removed by surgery) or metastatic
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.